In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma
-
Published:2020-09-11
Issue:9
Volume:17
Page:1164-1176
-
ISSN:1570-1808
-
Container-title:Letters in Drug Design & Discovery
-
language:en
-
Short-container-title:LDDD
Author:
Dehbarez Fatemeh Motamedi1, Nezafat Navid2, Mahmoodi Shirin1
Affiliation:
1. Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran 2. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
Background:
Hepatocellular Carcinoma (HCC) is a prevalent cancer in the world. As
yet, there is no medication for complete treatment of HCC.
Objective:
There is a critical need to search for an innovative therapy for HCC. Recently, multiepitope
vaccines have been introduced as effective immunotherapy approach against HCC.
Methods:
In this research, several immunoinformatics methods were applied to create an original
multi-epitope vaccine against HCC consisting of CD8+ cytolytic T lymphocytes (CTLs) epitopes
selected from α- fetoprotein (AFP), glypican-3 (GPC3), aspartyl-β-hydroxylase (ASPH); CD4+
helper T lymphocytes (HTLs) epitopes from tetanus toxin fragment C (TTFC), and finally, two tandem
repeats of HSP70407-426 were used which stimulated strong innate and adaptive immune responses.
All the mentioned parts were connected together by relevant linkers.
Results:
According to physicochemical, structural, and immunological results, the designed
vaccine is stable, non-allergen, antigen; it also has a high-quality 3D structure, and numerous linear
and conformational B cell epitopes, whereby this vaccine may stimulate efficient humoral immunity.
Conclusion:
Center on the collected results, the designed vaccine potentially can induce cellular and
humoral immune responses in HCC cases; nonetheless, the efficiency of vaccine must be approved
within in vitro and in vivo immunological analyzes.
Funder
Fasa University of Medical Sciences
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference75 articles.
1. Tsuchiya,N.; Yoshikawa,T.; Fujinami,N.; Saito,K.; Mizuno,S.; Sawada,Y.; Endo,I.; Nakatsura, T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology. 2017,6(10),e1346764. http://dx.doi.org/10.1080/2162402X.2017.1346764 PMID: 29123959 2. Liu,Q.; Yang,Y.; Tan,X.; Tao,Z.; Adah,D.; Yu,S.; Lu,J.; Zhao,S.; Qin,L.; Qin,L.; Chen, X. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Onco-target. 2017,8(15),24785-24796. http://dx.doi.org/10.18632/oncotarget.15806 PMID: 28445973 3. Wang,Q.; Luan,W.; Warren,L.; Kadri,H.; Kim, K.W.; Goz,V.; Blank,S.; Isabel Fiel,M.; Hiotis, S.P. Autologous tumor cell ly-sate-loaded dendritic cell vaccine inhibited tumor progression in an orthotopic murine model for hepatocellular carcinoma. Ann. Surg. Oncol. 2016,23(5) (Suppl. 5),574-582. http://dx.doi.org/10.1245/s10434-015-5035-9 PMID: 26786094 4. Arzumanyan,A.; Reis, H.M.; Feitelson, M.A. Pathogenic mecha-nisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer. 2013,13(2),123-135. http://dx.doi.org/10.1038/nrc3449 PMID: 23344543 5. Llovet, J.M.; Ricci,S.; Mazzaferro,V.; Hilgard,P.; Gane,E.; Blanc, J-F.; de Oliveira, A.C.; Santoro,A.; Raoul, J-L.; Forner,A.; Schwartz,M.; Porta,C.; Zeuzem,S.; Bolondi,L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath,I.; H?ussinger,D.; Giannaris,T.; Shan,M.; Moscovici,M.; Voliotis,D.; Bruix, J. SHARP Investiga-tors Study Group. Sorafenib in advanced hepatocellular carcinoma, N. Engl, J. Med. 2008,359(4),378-390. http://dx.doi.org/10.1056/NEJMoa0708857 PMID: 18650514
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|